Literature DB >> 6620483

Familial aggregation of lipids and lipoproteins and early identification of dyslipoproteinemia. The Collaborative Lipid Research Clinics Family Study.

J A Morrison, K Namboodiri, P Green, J Martin, C J Glueck.   

Abstract

We examined the hypothesis that familial aggregation of lipids and lipoproteins facilitates within-family identification and hyperlipoproteinemia. We studied 841 offspring and 1,236 siblings of normocholesterolemic probands, 833 offspring and 1,194 siblings of hypercholesterolemic probands, 806 offspring and 1,099 siblings of normotriglyceridemic probands, and 877 offspring and 1,108 siblings of hypertriglyceridemic probands in the Lipid Research Clinics Collaborative Family Study Program. As the categorization of probands' hypercholesterolemia or hypertriglyceridemia increased from sporadic, to persistent, to severe, the percentage of hypercholesterolemic or hypertriglyceridemic offspring and siblings increased. Close sibling and parent-offspring lipid and lipoprotein risk factor associations in hypercholesterolemic and hypertriglyceridemic family units during and after the period of shared common-household environment facilitate within-family identification of dyslipoproteinemia and suggest potential sharing of coronary heart disease risk.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6620483

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  3 in total

1.  Lipid screening in family practice: a critical appraisal of recent evidence.

Authors:  J W Sellors
Journal:  Can Fam Physician       Date:  1986-01       Impact factor: 3.275

Review 2.  Clinical relevance of reducing triglycerides. Implications for ischaemic heart disease treatment.

Authors:  A N Nafziger
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

3.  Cholesterol screening and family history of vascular disease.

Authors:  E D Primrose; J M Savage; C A Boreham; G W Cran; J J Strain
Journal:  Arch Dis Child       Date:  1994-09       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.